University of Sao Paulo
usp.brMatched: University of Sao Paulo General Hospital · University of Sao Paulo
Live pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
1,611
Active
177
Phase 3
109
Total enrollment
373,599
Pipeline matrix
Showing 40 of 49 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Pneumococcal Vaccine | — | — | — | — | — | 2 | |
| Acyclovir | — | — | — | — | — | 2 | |
| Eszopiclone 3 mg | — | — | — | — | — | 2 | |
| Everolimus | — | — | — | — | — | 2 | |
| Recombinant Herpes Zoster Vaccine | — | — | — | — | — | 1 | |
| Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | — | 1 | |
| Amoxicillin | — | — | — | — | — | 1 | |
| Meningococcal B | — | — | — | — | — | 1 | |
| Recombinant Zoster Vaccine | — | — | — | — | — | 1 | |
| clonidine | — | — | — | — | — | 1 | |
| clonazepam 0,25 mg | — | — | — | — | — | 1 | |
| Donepezil group | — | — | — | — | — | 1 | |
| Vasopressin intravenous | — | — | — | — | — | 1 | |
| Norepinephrine intravenous | — | — | — | — | — | 1 | |
| Vitamin B Complex | — | — | — | — | — | 1 | |
| standard maintenance immunosuppression | — | — | — | — | — | 1 | |
| Intravenous Esketamine | — | — | — | — | — | 1 | |
| Dengue 1,2,3,4 (attenuated) vaccine | — | — | — | — | — | 1 | |
| Promestriene Vaginal | — | — | — | — | 2 | ||
| Clopidogrel | — | — | 5 | ||||
| Dapagliflozin | — | — | — | — | 2 | ||
| Cabergoline | — | — | — | — | — | 2 | |
| testosterone pellet | — | — | — | — | — | 1 | |
| Control Arm | — | — | — | — | — | 1 | |
| Experimental arm | — | — | — | — | — | 1 | |
| Dendritic Cell Vaccine | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| Lacosamide | — | — | — | — | — | 1 | |
| Ayahuasca | — | — | — | — | 4 | ||
| Esketamine | — | — | — | — | 4 | ||
| StrepIncor | — | — | — | — | — | 1 | |
| Autologous CD19-Directed CAR-T Cells Manufactured at Ribeirão Preto Blood Center | — | — | — | — | — | 1 | |
| CART-19 | — | — | — | — | — | 1 | |
| Subcutaneous Testosterone Implants | — | — | — | — | — | 1 | |
| CTZ Paste | — | — | — | — | — | 1 | |
| Intervention1: Cannabidiol | — | — | — | — | — | 1 | |
| Intervention 2: Placebo | — | — | — | — | — | 1 | |
| Selexipag | — | — | — | — | 2 | ||
| Spironolactone | — | — | — | — | 2 |
9 more active programs hidden
Next readouts
- 2023-05-18
- 2024-05-06
- 2024-08
- 2024-09-01
- 2024-09-30
- 2024-12-11
- 2025-06
- 2025-07-30
- 2025-07-30
- 2025-12-01
Top conditions
- Obesity40
- Heart Failure33
- Dental Caries27
- Coronary Artery Disease24
- Pain23
- Stroke21
- Parkinson Disease19
- Quality of Life19
Frequently asked questions about University of Sao Paulo
- How many clinical trials does University of Sao Paulo have on ClinicalTrials.gov?
- University of Sao Paulo is listed as the lead sponsor on 1,611 clinical trials in ClinicalTrials.gov, 177 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Sao Paulo's trials are in Phase 3?
- 109 of University of Sao Paulo's trials are in Phase 3, spread across 49 active drug programs.
- What therapeutic areas does University of Sao Paulo focus on?
- University of Sao Paulo's most-studied conditions on ClinicalTrials.gov are Obesity, Heart Failure, Dental Caries, Coronary Artery Disease, Pain.
- When are University of Sao Paulo's next clinical trial readouts?
- University of Sao Paulo has 10 upcoming primary-completion readouts tracked here; the soonest is “Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease”, expected around 2023-05-18.